Key result
Fixed-dose amlodipine/benazepril combination therapy significantly improved large-vessel compliance compared to enalapril monotherapy (52% vs 32%; p<0.05).
Why the study?
Does fixed-dose amlodipine/benazepril combination therapy improve arterial compliance compared to enalapril monotherapy in hypertensive patients with type 2 diabetes?
RCT (n=20)
Double-blind
Does fixed-dose amlodipine/benazepril combination therapy improve arterial compliance compared to enalapril monotherapy in hypertensive patients with type 2 diabetes?
Absolute Event Rate: 52% vs 32%
p-value: p=<0.05
In patients with hypertension and type 2 diabetes, combination therapy with amlodipine and benazepril provides greater improvements in large-vessel compliance than enalapril monotherapy, independent of blood pressure lowering.
Combination ACEI/CCB therapy yields greater large-vessel compliance gains than ACEI monotherapy in diabetic hypertension; extends evidence for additive vascular effects independent of BP reduction.
Assessment of vascular compliance may be a useful measurement of the clinical effects of antihypertensive treatment. Both angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers are known to improve vascular elasticity. A study was performed to test the hypothesis that combined therapy with an ACE inhibitor and a calcium channel blocker would have additive benefits on vascular compliance at similar levels of blood pressure (BP), as compared with monotherapy with an ACE inhibitor. This 12-week, double-blind study was a substudy of a larger clinical hypertension study conducted in patients with hypertension and type 2 diabetes. Subjects (N = 20) were randomized to either a fixed-dose combination of amlodipine besylate/benazepril HCl or to enalapril monotherapy. BP, heart rate, large- and small-vessel compliance, systemic vascular resistance, and urinary microalbumin excretion were assessed at baseline and after treatment. Both treatments were similarly effective in lowering BP, reducing systemic vascular resistance, and decreasing urinary microalbumin excretion. Improvement in large-vessel compliance was significantly greater among subjects who received ACE-inhibitor/calcium channel blocker combination therapy (52%) as compared with those who received ACE-inhibitor monotherapy (32%; p < 0.05). No significant change in small-vessel compliance was observed with either treatment. Greater improvement in large-vessel compliance with combination therapy was independent of BP lowering.
No takes yet. Share an insight, caveat, or question.
Winer et al. (2005) conducted an RCT in Hypertension and type 2 diabetes (n=20). Fixed-dose combination of amlodipine besylate/benazepril HCl vs. Enalapril monotherapy was evaluated on Improvement in large-vessel compliance (p=<0.05). Fixed-dose amlodipine/benazepril combination therapy significantly improved large-vessel compliance compared to enalapril monotherapy (52% vs 32%; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: